Catharina Svanborg

This inventor holds 14 USPTO granted patents and 13 published patent applications and 11 EPO patents. Top assignees: Hamlet Pharma Ab, Nya Hamlet Pharma Ab, Linnane Pharma Ab. Active years: 2006-2025.

USPTO Granted Patents = 14 (Patent Applications = 13)

% Patents Active = 85.7

EPO Patents = 11 (Patent Applications = 17)

Average Co-Inventor Count = 2.3

ph-index = 2

Forward Citations = 42(Granted Patents)

Location History:

Lund, SE (2006 - 2016)
Malmo, SE (2019 - 2024)

Company Filing History:

Selectimmune Pharma Ab

patent

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12331073 - Preparation of biologically active complexes (2025-06-17),

2. 11865161 - Prophylactic and nutraceutical therapy (2024-01-09),

3. 11752192 - Inhibitor of RNA polymerase II (2023-09-12),

4. 11103561 - Prophylactic and nutraceutical therapy (2021-08-31),

5. 11013786 - Therapy (2021-05-25),

6. 10287585 - Therapy (2019-05-14),

7. 9487561 - Biologically active complex and its preparation (2016-11-08),

8. 9085643 - Biologically active complex and its preparation (2015-07-21),

9. 8796218 - Complex and production process (2014-08-05),

10. 7713533 - Active complex of α-lactalbumin (HAMLET) and cofactor (2010-05-11),

11. 7524932 - Lactalbumin production process (2009-04-28),

12. 7270822 - Active complex of alpha-lactalbumin (hamlet) and cofactor (2007-09-18),

13. 7144855 - Protein complex from ion-exchange chromatography for treatment of bacterial infections (2006-12-05),

14. 7053185 - Lactalbumin production process (2006-05-30),

Title: **Inventor Catharina Svanborg: A Leader in Biologically Active Complexes**

Introduction

Catharina Svanborg, based in Lund, Sweden, is a prolific inventor with a remarkable portfolio of 14 patents. Her innovations primarily focus on biologically active complexes and their application in therapeutic contexts, particularly concerning cancer treatment.

Latest Patents

Among her latest inventions, Svanborg has developed a method for the preparation of biologically active complexes. This innovative method involves dissolving a mixture of polypeptides, such as alphalactalbumin, along with oleic acid and suitable salts in an aqueous solvent enriched with multiple salts. Notably, this preparation does not necessitate extensive heating, making the process both simple and efficient.

Additionally, Svanborg has created a biologically active complex intended for prophylactic and nutraceutical therapy. This complex comprises a polypeptide derived from naturally occurring proteins, modified to enhance its efficacy against cancers, especially those of the gastrointestinal tract. The invention includes compositions obtainable from milk or milk fractions, further underscoring its versatility in the nutraceutical market.

Career Highlights

Throughout her career, Catharina Svanborg has contributed to the field of biotechnology through her work at Hamlet Pharma AB and Nya Hamlet Pharma AB. Her inventive contributions have made a significant impact on developing therapeutic methods and enhancing our understanding of biologically active compounds.

Collaborations

In her innovative pursuits, Svanborg has collaborated with notable colleagues, including Chin Shing Ho and Kenneth Hun Mok. These partnerships have fostered a dynamic exchange of ideas and have been instrumental in advancing her research and patent applications.

Conclusion

Catharina Svanborg's contributions to the field of biologically active complexes exemplify her commitment to innovation and therapeutic advancement. With a solid foundation of patents and collaborations, she continues to pave the way for future discoveries that may revolutionize cancer prevention and treatment methodologies.